Gene · 644079
Papers2,404
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,404
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Studies on absorption mechanism and pharmacokinetic properties of albendazole-bile acid conjugate: In vivo and in vitro. | Biomed Pharmacother | 2024 | 39243427 | PubTator, text mining | PubMed |
| Dual inhibition of topoisomerase II and microtubule of podophyllotoxin derivative 5p overcomes cancer multidrug resistance. | Eur J Pharmacol | 2024 | 39233039 | PubTator, text mining | PubMed |
| Pharmacokinetic Simulation and Area under the Curve Estimation of Drugs Subject to Enterohepatic Circulation. | Pharmaceutics | 2024 | 39204389 | PubTator, text mining | PubMed |
| Pseudomonas aestus Isolation from the Nasal Cavity of a Cat with Chronic Rhinitis. | Vet Sci | 2024 | 39195836 | PubTator, text mining | PubMed |
| In Vivo Activity of Intestinal P-Glycoprotein and Hepatic Organic Anion Transporters Polypeptide in Pregnancy and Postpartum. | J Clin Pharmacol | 2024 | 39189980 | PubTator, text mining | PubMed |
| Organoids and tissue/organ chips. | Stem Cell Res Ther | 2024 | 39098898 | PubTator, text mining | PubMed |
| Highly restrictive and directional penetration of the blood cerebral spinal fluid barrier by JCPyV. | PLoS Pathog | 2024 | 39038049 | PubTator, text mining | PubMed |
| Terpenoids from quinoa reverse drug resistance of colon cancer by upregulating miR-495-3p. | J Sci Food Agric | 2024 | 38962946 | PubTator, text mining | PubMed |
| Applicability of MDR1 Overexpressing Abcb1KO-MDCKII Cell Lines for Investigating In Vitro Species Differences and Brain Penetration Prediction. | Pharmaceutics | 2024 | 38931858 | PubTator, text mining | PubMed |
| The Anthraquinone Derivative C2 Enhances Oxaliplatin-Induced Cell Death and Triggers Autophagy via the PI3K/AKT/mTOR Pathway. | Int J Mol Sci | 2024 | 38928176 | PubTator, text mining | PubMed |
| Silencing LINC00987 ameliorates adriamycin resistance of acute myeloid leukemia via miR-4458/HMGA2 axis. | Biol Direct | 2024 | 38910243 | PubTator, text mining | PubMed |
| Effects of allopurinol and febuxostat on uric acid transport and transporter expression in human umbilical vein endothelial cells. | PLoS One | 2024 | 38905201 | PubTator, text mining | PubMed |
| BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. | Cell Commun Signal | 2024 | 38872211 | PubTator, text mining | PubMed |
| Strategies for enhanced gene delivery to the central nervous system. | Nanoscale Adv | 2024 | 38868835 | PubTator, text mining | PubMed |
| Effect of Antioxidants in Medicinal Products on Intestinal Drug Transporters. | Pharmaceutics | 2024 | 38794309 | PubTator, text mining | PubMed |
| Multidrug resistance transporters P-gp and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer cells. | Front Pharmacol | 2024 | 38756373 | PubTator, text mining | PubMed |
| Correction to "Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier". | Drug Metab Dispos | 2024 | 38754962 | PubTator, text mining | PubMed |
| A face-to-face comparison of the BBB cell models hCMEC/D3 and hBMEC for their applicability to adenoviral expression of transporters. | J Neurochem | 2024 | 38735840 | PubTator, text mining | PubMed |
Risk of Enzyme- and Transporter-mediated Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2022: A Detailed Analysis of In Vitro and Clinical Data Available in New Drug Application Reviews. | Clin Ther | 2024 | 38734524 | PubTator, text mining | PubMed |
Survey of Pharmaceutical Industry's Best Practices around In Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group. | Drug Metab Dispos | 2024 | 38697852 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/644079/papers?page=7